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Abstract
Background Secondary acute myeloid leukemia (sAML) describes patients
(pts) with a history of malignant or non-malignant disease or AML secondary
to environmental, occupational or therapeutic exposures. They are generally
associated with poor outcome despite the use of intensive treatments. The
impact of clinical features and type of treatment on pts' outcome is still not
well established. In the current analysis we evaluated sAML pts who were
treated in 13 EORTC collaborative trials conducted between May 1986 and
January 2008. sAML pts in the database were pooled to characterize clinical
features of the disease and evaluate changes in survival over these years
(yrs).
Method Main selection criteria were AML with bone marrows blasts ≥20% and
documented history of prior malignancy, non-malignant disease and/or toxic
exposure. AML-M3 and MDS without confirmed diagnosis ≥2 months before
AML were excluded. All pts were eligible for standard treatment. Induction
regimens were anthracycline and AraC based: 7+3, including etoposide,
intensified with high dose (HD)-AraC randomized to standard doses (SD) in
younger (AML12) or gemtuzumab ozogamicin in elderly pts. Consolidation
regimens were age adapted. In mid-1980s, autologous transplant was tested
vs a 2  consolidation cycle (AML8A) in pts ≤45 yrs and thereafter used
systematically in pts ≤60 yrs without available donor. Allogeneic transplant
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(Allo-SCT) was offered to pts ≤46 yrs with HLA-compatible sibling since mid-
1980s and expanded in the last decade to pts up to 59 yrs.
Selected pts were divided into 3 sAML cohorts, cohort A after MDS, cohort B
after other malignant diseases and cohort C after non-malignant conditions
and/or toxic exposure.
Results Of 8858 pts enrolled in the 13 evaluated studies, 962 were sAML.
Median age was 63 yrs (range 16-85), 413 were young (≤60 yrs) and 549
were elderly (≥61 yrs); 54% were males. Cohort A consisted of 509 pts
(median age 64 yrs), cohort B of 362 pts (median age 59 yrs) and cohort C of
91 pts (median age 61 yrs). In cohort B, breast cancer (24%) and lymphoma
(14%) were the most frequent primary tumors. Autoimmune diseases
represented 22% of non-malignant conditions.
In young pts, complete remissions (CR/CRi) rate was 59%; 55% in SD-AraC vs
89% in HD-AraC treated pts. Allo-SCT in CR1 was performed in 21% of all pts.
The Allo-SCT rate increased from 5% before 1990, 20% in 1990-1999 to 25%
from 2000 (20% in SD-AraC vs 31% of HD-AraC treated pts).
CR/CRi was achieved in 45% of elderly pts.
Median follow-up was 6 yrs. Median overall-survival (OS) was 14.5 months in
young and 9 months in elderly pts. The 5-yr OS was 28% and 7% respectively.
Five-yr OS was 11% in cohort A and 22% in both cohort B and C.
Treatment outcome of younger pts according to disease features and
treatment type over time in cohort A and B are detailed in table 1 & 2. Using
Cox model stratified by cohort age, gender, WBC, risk group, year of
treatment and HD-AraC were independent prognostic factors for OS. In the
AML12 study, compared to denovo pts, sAML pts ≤45 yrs had worse outcome
if treated with SD-AraC whereas a better OS was seen if treated with HD-AraC.
Table1
Univariate analysis of OS for young pts
Table2
Multivariate analysis of OS for young pts in cohort A and B
In elderly pts only the good/intermediate risk group of cohort B had a
relatively better 5-yr OS (15%).
Conclusions The outcome of sAML in younger pts has improved over the yrs
in parallel with HD-AraC introduction in induction of remission. HD-AraC
should be considered for younger pts with sAML.
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